Show simple item record

dc.contributor.authorNguyen, TH
dc.contributor.authorGuedj, J
dc.contributor.authorAnglaret, X
dc.contributor.authorLaouénan, C
dc.contributor.authorMadelain, V
dc.contributor.authorTaburet, AM
dc.contributor.authorBaize, S
dc.contributor.authorSissoko, D
dc.contributor.authorPastorino, B
dc.contributor.authorRodallec, A
dc.contributor.authorPiorkowski, G
dc.contributor.authorCarazo, S
dc.contributor.authorConde, MN
dc.contributor.authorGala, JL
dc.contributor.authorBore, JA
dc.contributor.authorCarbonnelle, C
dc.contributor.authorJacquot, F
dc.contributor.authorRaoul, H
dc.contributor.authorMalvy, D
dc.contributor.authorde Lamballerie, X
dc.contributor.authorMentré, F
dc.date.accessioned2017-02-28T21:36:41Z
dc.date.available2017-02-28T21:36:41Z
dc.date.issued2017-02-23
dc.date.submitted2017-02-27
dc.identifier.citationFavipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted. 2017, 11 (2):e0005389 PLoS Negl Trop Disen
dc.identifier.issn1935-2735
dc.identifier.pmid28231247
dc.identifier.doi10.1371/journal.pntd.0005389
dc.identifier.urihttp://hdl.handle.net/10144/618815
dc.description.abstractIn 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.
dc.language.isoenen
dc.publisherPLoSen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseases.en
dc.titleFavipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeteden
dc.identifier.journalPLoS Neglected Tropical Diseasesen
refterms.dateFOA2019-03-04T13:12:42Z
html.description.abstractIn 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.


Files in this item

Thumbnail
Name:
Nguyen T et al - 2017 - Favipiravir ...
Size:
1.609Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record